newsfilter
← Latest News
Business Wire·

Humanigen Reports Third Quarter and Nine Months Ending September 30, 2021 Financial Results and Provides Corporate Update

Humanigen, Inc. (NASDAQ:HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‛cytokine storm' with its lead drug candidate, lenzilumab, today provided a corporate and regulato